Department of Rheumatology and Immunology, Shenzhen People's Hospital, The Second Clinical Medical College of Jinan University, The First Affiliated Hospital of Southern University of Science and Technology, Shenzhen, 518020, People's Republic of China.
Department of Rheumatology and Clinical Immunology, Peking Union Medical College Hospital, Peking Union Medical College & Chinese Academy of Medical Science, National Clinical Research Center for Dermatologic and Immunologic Diseases (NCRC-DID), Beijing, 100730, People's Republic of China.
Clin Rheumatol. 2021 Jul;40(7):2965-2971. doi: 10.1007/s10067-020-05489-3. Epub 2020 Nov 5.
Thrombotic events are the most frequent causes of death in patients with antiphospholipid syndrome (APS). Previous studies have reported infection to be the most important trigger of thrombosis in APS, with molecular mimicry considered to be a major mechanism. Although timely management of infections has been recommended in patients with high suspicion of infection, anti-infective therapy would not take effect in a short time due to the dilemma in determining the origins of infection, especially in patients undergoing immunosuppressive therapy. Here, we describe a 26-year-old patient with systemic lupus erythematosus with triple antiphospholipid antibody positivity who had a stroke involving her dorsolateral medulla, despite timely anti-infective treatment within the context of skin infection caused by Stenotrophomonas maltophilia. To the best of our knowledge, it is the first report about the association between Stenotrophomonas maltophilia infection and thrombotic complications in APS. Thus, solely focusing on anti-infective therapy by the current recommendation for the management of APS may be insufficient within the context of infection; early initiation of effective anticoagulation should also be suggested until the anti-infective therapy becomes effective, especially in patients with high-risk antiphospholipid antibody profiles, in whom the potential benefit would outweigh the risk of bleeding.
血栓事件是抗磷脂综合征(APS)患者最常见的死亡原因。先前的研究报告感染是 APS 血栓形成的最重要诱因,而分子模拟被认为是主要机制。尽管建议对高度怀疑感染的患者进行及时的感染管理,但由于确定感染来源的困境,特别是在接受免疫抑制治疗的患者中,抗感染治疗在短时间内不会生效。在这里,我们描述了一位 26 岁的系统性红斑狼疮患者,她的抗磷脂三抗体阳性,尽管在嗜麦芽窄食单胞菌引起的皮肤感染背景下及时进行了抗感染治疗,但仍发生了累及背外侧髓质的中风。据我们所知,这是关于嗜麦芽窄食单胞菌感染与 APS 血栓并发症之间关联的首例报告。因此,仅根据当前 APS 管理建议进行抗感染治疗可能是不够的;应在抗感染治疗生效之前,尽早开始有效的抗凝治疗,尤其是在具有高风险抗磷脂抗体谱的患者中,因为潜在的益处将超过出血风险。